ANDA Submissions Drop To Start FY 2021, Perhaps Forced Down By COVID-19
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
You may also be interested in...
Will the growing workload cause GDUFA fees to increase or prompt other changes?
Dan Leonard is working on post-pandemic generic drug issues, using coronavirus as a way to get in front of lawmakers.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.